Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Remote Patient Monitoring with Digital Medicine Society

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The Digital Medicine Society (DiMe) is a global nonprofit specializing in the advancement of ethical, effective, equitable, and safe use of digital technology for redefining healthcare and optimizing lives. Jennifer Goldsack, CEO of DiMe, spoke with Intel’s Head of Global Health Solutions Alex Flores on the advancements in remote patient monitoring and the role technology plays in this.

Remote patient monitoring allows parsing out different digital phenotypes within certain disease states to effectively match treatment with the patient. Goldsack says, “In those broad disease states, where there’s very little that we can do to either ameliorate symptoms of the disease or cure the disease — something like Parkinson’s or Alzheimer’s disease. We’re hopeful that these new measures can start to advance the field.”

Goldsack believes there is a much more practical reason for remote patient monitoring to become an essential focus of care: the evolving role and methods of healthcare today.

“We must start thinking about how we can start to monitor people’s health outside the clinic walls,” she explains. “How can we think about patients with complex chronic diseases who may have episodic conditions with flare-ups? How can we monitor their well-being and health performance under clinicians’ care without bringing them into the hospital every time?”

The reality that healthcare presently faces is a shortage of doctors and clinicians to treat the number of patients. Remote patient care is one healthcare solution that helps ensure the patient gets the best care possible, even with reduced resources available. “We can use remote patient monitoring to get early signals… [and] we can intervene and care for them before those outcomes become bad and before they become pricey,” Goldsack says.

The technology behind remote patient monitoring must be high quality to make high-quality clinical decisions. Clinical validation of the gathered data is vital in this process. Goldsack says it’s also crucial that the technology deployed is an affordable solution, because if it isn’t, then it won’t be sustainable.

In terms of utilizing AI in the remote patient monitoring process, Goldsack says there is unlimited potential. Still, it is important to keep things in perspective and focus on the most critical challenges first. “We should look at the ability to identify particular phenotypes within large population-level data sets,” she notes. “AI might be able to tell us if we deliver the right data that some patients do well, and for whatever reasons, some patients end up having a fall and an injury and come back into the hospital within four weeks. It might be that we have no idea what the differences are between those patients who fall and those who don’t.” AI could help make those determinations.

Learn more about remote patient monitoring by connecting with Jennifer Goldsack or Alex Flores on LinkedIn or visit: 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Health and Life Sciences at the Edge.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512